The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edema
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 03 Apr 2017 Status changed from active, no longer recruiting to completed.
- 17 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2015 New trial record